QIAGEN (QGEN) and Myriad Genetics (MYGN) announced a new master collaboration agreement to develop companion diagnostic tests in the field of cancer. The partnership aims to deliver innovative services and products to pharmaceutical companies, enabling the development and commercialization of proprietary cancer tests for the U.S. clinical market, and providing distributable companion diagnostic test kits for the global market. The alliance between QIAGEN and Myriad brings together the respective strengths of each partner. Myriad leverages its CLIA-certified, CAP-accredited lab platform, assay development expertise and robust commercial infrastructure for clinical sample testing. QIAGEN will provide Sample to Insight solutions, including sample preparation, its PCR, digital PCR, QIAseq next-generation sequencing technologies, instruments, as well as the QIAGEN Digital Insights portfolio of bioinformatics.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on QGEN:
- Qiagen price target lowered to $50 from $55 at JPMorgan
- QIAGEN N.V. to release results for Q3 2023 and hold webcast
- QIAGEN launches QuantiFERON-EBV RUO assay, facilitating research of cell-mediated immune response to Epstein-Barr virus
- Qiagen price target lowered to $58 from $64 at HSBC
- Qiagen extends AI capabilities of QCI Interpret